Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL7P30 is a processed pseudogene of the ribosomal protein L7 gene family. Pseudogenes arise when gene copies become functionally inactive due to disablements such as frameshifts or premature stop codons. RPL7P30 does not produce a functional protein and is not known to have any biological function or role in disease, nor is it considered a therapeutic target. The parent gene, RPL7, encodes a structural component of the 60S ribosomal subunit essential for protein synthesis, but the pseudogene does not contribute to these activities. RPL7P30 is a non-functional pseudogene, not a receptor, enzyme, or therapeutically actionable target. There is nothing to suggest it is involved in disease, drug action, or considered for biomarker or safety relevance. Entries listing RPL7P30 as a drug target or disease gene are incorrect; this is a common issue with pseudogene annotations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 30 (RPL7P30).